Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Non-Current Debt: 2011-2015

Historic Non-Current Debt for Ligand Pharmaceuticals (LGND) over the last 4 years, with Dec 2015 value amounting to $205.4 million.

  • Ligand Pharmaceuticals' Non-Current Debt was N/A to $445.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.5 million, marking a year-over-year change of. This contributed to the annual value of $205.4 million for FY2015, which is 4.83% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Non-Current Debt of $205.4 million as of FY2015, which was up 4.83% from $195.9 million recorded in FY2014.
  • Over the past 5 years, Ligand Pharmaceuticals' Non-Current Debt peaked at $205.4 million during FY2015, and registered a low of $13.4 million during FY2012.
  • Moreover, its 2-year median value for Non-Current Debt was $200.6 million (2014), whereas its average is $200.6 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first crashed by 33.73% in 2012, then increased by 4.83% in 2015.
  • Yearly analysis of 4 years shows Ligand Pharmaceuticals' Non-Current Debt stood at $20.3 million in 2011, then crashed by 33.73% to $13.4 million in 2012, then reached $195.9 million in 2014, then rose by 4.83% to $205.4 million in 2015.